title: Update on the management of rosacea: a status report on the current role and new horizons with topical azelaic acid.
abstract: Azelaic acid (AzA) 15% gel has been available in the United States for slightly over a decade, approved for treatment of the inflammatory lesions (papules and pustules) of rosacea. Efficacy and safety have been established in multiple studies both as monotherapy and in combination with oral doxycycline. Azelaic acid 15% gel has been shown not to induce epidermal permeability barrier impairment, and proper skin care reduces the likelihood of neurosensory adverse effects of stinging and burning that can affect a subset of patients with rosacea. Azelaic acid 15% gel appears to produce a quicker onset of clinical effect than metronidazole in some patients when either agent is used in combination with subantimicrobial dose doxycycline; however, both topical agents are effective when used in this combination approach for papulopustular rosacea (PPR). Although more information is needed on the modes of action of AzA in the treatment of rosacea, downregulation of the cathelicidin pathway appears to be one operative mode of action based on in vitro and in vivo studies, including data from patients treated with AzA 15% gel for PPR. Azelaic acid 15% foam is currently in the latter stages of development for PPR, with pivotal studies demonstrating efficacy and favorable tolerability, including a very low incidence of stinging, burning, and itching even without the use of designated skin care products.
authors.forename: James Q
authors.initials: JQ
authors.lastname: Del Rosso
authors.forename: Leon H
authors.initials: LH
authors.lastname: Kircik
mesh_terms: D000279:Administration, Cutaneous; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003998:Dicarboxylic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004318:Doxycycline / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005782:Gels; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage; D012393:Rosacea / Q000188:drug therapy* / Q000473:pathology
chemical_list: D003879:Dermatologic Agents; D003998:Dicarboxylic Acids; D005782:Gels; D008795:Metronidazole; C010038:azelaic acid; D004318:Doxycycline